Abstract A 68-year-old man, who was a patient with established rheumatoid arthritis (RA) with RA-associated interstitial lung disease (RA-ILD) and pulmonary emphysema, began taking tocilizumab. Subsequently, he developed dyspnea parallel to improvement of RA. At 10 months after the administration of tocilizumab, he was urgently admitted because of exacerbation of ILD. He died despite receiving steroid pulse therapy and antibiotic therapy on a respirator. This is the Wrst case report to describe the exacerbation of ILD during treatment with tocilizumab in the postmarketing surveillance (PMS) period.
Introduction
Tocilizumab is a humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody that blocks IL-6 from binding to its receptor [1] . Japanese [2, 3] and Euramerican [4] [5] [6] [7] randomized control trials (RCT) have elucidated the eYcacy as well as safety of tocilizumab therapy in patients with rheumatoid arthritis (RA). However, patients with RA in RCT had a lower rate of risk factors for adverse eVects than in postmarketing surveillance (PMS) in general [8] . Therefore, it is necessary to accumulate clinical information on "real-world" RA cases treated with tocilizumab in Japan starting now.
In this report, we describe a patient with established RA with chronic respiratory failure caused by RA-associated interstitial lung disease (RA-ILD) and pulmonary emphysema, who was administrated tocilizumab during PMS. He died of acute exacerbation of ILD during treatment with tocilizumab.
Case report
The patient was a 68-year-old Japanese man who had been diagnosed with RA in 2003 and treated sequentially with salazosulfapyridine (SASP). He also had RA-ILD and pulmonary emphysema. RA-ILD was classiWed as usual interstitial pneumonia (UIP) by the transbronchial lung biopsy (TBLB) specimens. He had a history of smoking thirty cigarettes a day for 40 years. He was administered home oxygen therapy because of chronic respiratory failure. He was treated with leukocyte aphaeresis against RA in May 2004. Although he began taking etanercept in February 2006, RA disease activity remained high. In July 2008, he was unable to move because of polyarthralgia and was urgently admitted to our hospital. Treatment for his RA was switched from etanercept to tocilizumab. The clinical course after the administration of tocilizumab is shown in Fig. 1 . Although no therapeutic eYcacy was obtained (disease activity score of 28 joints; DAS28 > 5.1), DAS28 and C-reactive protein (CRP) tended to decrease from 5 months after the administration of tocilizumab. After 8 months, a moderate response in the clinical eYcacy of tocilizumab according to the criteria set by the European League against Rheumatism (EULAR) was seen, and the CRP levels dropped to negative values. However, he was admitted to our hospital in March 2009 because of increased dyspnea on exertion. Although image Wndings did not show exacerbation of RA-ILD and pulmonary emphysema, pulmonary function test showed remarkable diVusion disturbance; vital capacity (VC) of 91.8%, forced expiratory volume in 1.0 s (FEV 1.0 ) of 79.6% and diVusion capacity of the lungs for carbon monoxide of 17.9%.
On May 6 2009, he was urgently re-admitted to our hospital because of acute exacerbation of dyspnea. On admission, temperature was 36.4°C, pulse 93/min, respiration 20/ min and blood pressure 109/70 mmHg. Saturation oxygen by pulse oximetry showed 85% at rest and 70% on exertion in 6 L/min of oxygen. Fine crackles were heard on the bilateral lung. Edema was not found. The biochemical and serological data are shown in Table 1 . The white blood count elevated at 14,000/mm 3 , but CRP was negative. KL-6, SP-D and SP-A were elevated. Although -D glucan slightly elevated at 23.3 pg/ml, candida antigen, cryptococcal antigen and aspergillus antigen were all negative. The culture of the sputum and polymerase chain reaction (PCR) for Pneumocystis jiroveci of the bronchoalveolar lavage Xuid (BALF) were also negative. Chest X-ray (Fig. 2a) and computed tonography (CT, Fig. 2b ) on admission showed no remarkable change. On the following day, he was put on an artiWcial respirator because of worsening respiratory failure, and chest X-ray (Fig. 2c) and CT ( 
Discussion
The present case was elderly and had established RA with preexisting ILD. He was administered tocilizumab because he was refractory to several DMARDs, but died from exacerbation of ILD at ten months after initiation of the tocilizumab therapy. DiVerential diagnoses included opportunistic infection, particularly pneumocystis pneumonia (PCP), drug-induced lung injury and exacerbation of RA-ILD. The exacerbation of ILD after administration of anti-tumor necrosis factor (TNF) agents was recently reported [9] [10] [11] . Older age and preexisting ILD are risk factors for anti-TNF agent-induced ILD [9] . Although tocilizumab is one of the new biologic DMARDs following anti-TNF agents, the mechanism of action of tocilizumab that improves RA is diVerent from that of anti-TNF agents. In clinical studies such as the SAMU-RAI trial [2] and SATORI trial [3] in Japan, and the AMBITION trial [6] , the TOWARD trial [5] and the RADIATE trial [7] in Europe and the United States, no patient developed ILD including PCP. However, one patient developed ILD and another developed PCP in the OPTION trial [4] . The former patient recovered rapidly on appropriate therapy. The latter patient had a history of chronic obstructive pulmonary disease. The PMS of inXiximab and etanercept revealed incidences of PCP in Japanese patients with RA that were higher (0.4 and 0.2%, respectively) than in Western countries [8] . The risk factors of PCP in patients with RA treated with inXiximab were older age (=65 years), high dosage of PSL (=6 mg/ day) and pulmonary comorbidities in Japan [12, 13] . Wolfe et al. [14] reported that the risk factors of pneumonia hospitalization in patients with RA were prednisolone (PSL) use, older age and the presence of pulmonary comorbidities and diabetes. The RA-ILD is frequent in patients who are older, male, smokers and have a high titer of the rheumatoid factor. The acute exacerbation of RA-ILD results in a high fatality rate regardless of the therapy used. However, disease activity of RA is often uncontrolled when there is an acute exacerbation of RA-ILD. On the other hand, disease activity of RA is often strongly suppressed by treatment when as opportunistic infection and drug-induced exacerbation occur. In the present case, it was diYcult to deWne the cause of the exacerbation of ILD. Because -D glucan remarkably elevated during the course of therapy and the patient had many risk factors for PCP, an older age (=65 years), high dosage of PSL (=6 mg/day) and pulmonary comorbidities, it is highly possible that PCP caused the exacerbation of ILD. Furthermore, the exacerbation might also be induced by opportunistic infection or drug-induced lung injury, because he had developed respiratory failure parallel to expression of the eYcacy of tocilizumab. 
